The Cancer Letter

Inside information on cancer research and drug development

In Brief

Wistar’s Nan Zhang and Noam Auslander receive $1.2M in biomedical research grants from V Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Nan Zhang

Noam Auslander

Nan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases. 
By Jamillah Hoy-Rosas
In the Archives

In 1990, “political oncologist” Helene Brown predicted the future. Did she get it right?

When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.
By Katie Goldberg
ClinicalTrials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy. 
By Michael P. Castro
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account